Philogen SpA (78Q) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Philogen SpA DE:78Q is currently developing the following drugs: L19il2/L19tnf, L19tnf, L19il2/L19tnf, L19il2, F8il10, L19tnf, L19tnf And Tmz, L19tnf And Ccnu, L19tnf Monotherapy, L19tnf And Tmz In Recurrent Astrocytoma, L19tnf And Ccnu In Recurrent Astrocytoma, L19tnf Monothery In Recurrent Oligodendroglioma, [68Ga]Ga-Oncoacp3, [68Ga]Ga-Oncocaix, L19il2, [177Lu]Lu-Oncofap-23, Lomustine, L19tnf, L19tnf, L19il2/L19tnf, L19il2, Keytruda, [68Ga]Ga-Oncofap Administration, F16il2, Nivolumab, Fixed Dose, Lomustine, Onfekafusp Alfa, Dacarbazine, Onfekafusp Alfa, Doxorubicin, Onfekafusp Alfa, Il12-L19l19, Temozolomide, Onfekafusp Alfa, L19il2 +L19tnf, Doxorubicin, L19tnf, L19tnf, Surgery, Daromun, Adjuvant Therapy, Doxorubicin, L19tnf Plus Doxorubicin, F16il2, Bi 836858, Rituximab, L19-Il2 - Ph I, L19-Il2 At Rd - Ph Ii, Cytarabine, F16il2, Surgery, L19il2 + L19tnf, F8il10, Mtx, Methotrexate, F8il10, Doxorubicin, L19tnfα, L19il2 - Ph I, L19il2 At Rd - Ph Ii, Dtic, Arm A: F16il2 In Combination With Paclitaxel, Arm B: Paclitaxel, Isolated Inferior Limb Perfusion, L19il2 Monoclonal Antibody-Cytokine Fusion Protein In Combination With Gemcitabine, F16il2 In Combination With Paclitaxel. These drug candidates are in various stages of clinical development as the company works toward FDA approval.